Coombes, R. Charles, Caballero, Otavia L., Shousha, Sami, Ghaem-Maghami, Sadaf, Woodley-Barker, Laura, Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158 and Neville, A. Munro 2017. NY-ESO-1 expression in DCIS: A new predictor of good prognosis. Oncoscience 10.18632/oncoscience.348 |
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (384kB) | Preview |
Abstract
Background: At present, it is difficult to predict which patients with ductal carcinoma-in-situ (DCIS) will subsequently develop frank invasive breast cancer (IDC). A recent survey by our group has shown that NY-ESO-1 and MAGEA are both expressed in DCIS. This study was aimed at determining whether expression of these antigens was related to the later development of IDC. Results: 14 of 42 (33%) of patients developed invasive breast cancer during the follow up period. Only one of those DCIS cases that relapsed was positive for NYESO-1 at diagnosis. In contrast, DCIS samples of 15 of the 28 (54%) of those patients who remained disease-free expressed NY-ESO-1. (Permutation chi square p=0.0033). Methods: We identified 42 patients with DCIS, and followed them up for more than 10 years. NY-ESO-1 and MAGEA were demonstrated by immunostaining as were CD8+ infiltrates on all sections together with the conventional markers, ER, PR, and HER2. Conclusions: Expression of NY-ESO-1 may predict those patients who will not subsequently develop invasive breast cancer and could therefore potentially be helpful in defining prognosis in patients with DCIS.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Centre for Trials Research (CNTRR) Medicine |
Publisher: | Impact Journals |
ISSN: | 2331-4737 |
Date of First Compliant Deposit: | 9 August 2019 |
Date of Acceptance: | 25 March 2017 |
Last Modified: | 06 Jan 2024 03:06 |
URI: | https://orca.cardiff.ac.uk/id/eprint/124774 |
Actions (repository staff only)
Edit Item |